Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04214860 · ClinicalTrials.gov registry record · Phase 1
APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
A Phase 1 study, sponsored by Aprea Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT04214860 is a Phase 1 study that has completed, run by Aprea Therapeutics. The registered enrollment target is 51 participants.
The verdict
NCT04214860, a Phase 1 study, has completed, sponsored by Aprea Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This clinical trial is a Phase I, open-label, dose-finding and cohort expansion study to determine the safety and preliminary efficacy of APR-246 in combination with venetoclax and azacitidine in patients with myeloid malignancies.
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG APR-246
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2022-01-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04214860
The ClinicalTrials.gov registry entry for NCT04214860 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aprea Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT04214860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04214860 about?
NCT04214860 is a clinical study titled "APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies". This clinical trial is a Phase I, open-label, dose-finding and cohort expansion study to determine the safety and preliminary efficacy of APR-246 in combination with venetoclax and azacitidine in patients with myeloid malignancies.
What is the current status of trial NCT04214860?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2019-12-13. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT04214860?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), APR-246 (DRUG).
Who is sponsoring clinical trial NCT04214860?
This trial is sponsored by Aprea Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.